Jeff Aronin’s Achievements

Jeff Aronin is the CEO and founder of Ovation Pharmaceuticals LLC. He created the company in 2000 after feeling that there was a way he could treat those who had unmet goals. Jeff Aronin graduated from the Northern Illinois University with a degree and MBA. He then joined the healthcare industry before starting his own company.

 

One day he was treating a child, and the situation made him make a lifetime decision. He was undecided between using medicine or a complex surgery on the child. He, however, chose to give medication a try. In the process, he saved the child from the complex process of surgery and improved the child’s condition. This encounter helped improve his passion for his patients. His core belief and drive is to help people lead a better life. He has achieved this by commercializing medicines to meet the unmet needs of patients.

 

The focus he has on drug development and patients is what sets apart his company from the rest. Most of the companies in pharmaceutical space and biotech are less concerned with addressing minor diseases. In 2009, Lundbeck offered to buy Ovation. The company was sold for $900 million. Lundbeck kept Jeff Aronin as CEO to assist in the transition. Due to his massive contribution, the company continues to enjoy a successful spell.

Aronin is also a leading incubator and investor in biotech companies. Paragon is focused on bringing medication to the market by building companies and identifying unmet needs. Paragon has helped build companies such as Harmony Biosciences and Castle Creek Pharmaceuticals.

 

Harmony Biosciences deals with disorders that affect the central nervous system. Castle Creek deals with genetic dermatology conditions. These companies have continued to prosper with the hope that one day they will meet the needs of patients.

 

Jeff Aronin has supported the community in many ways. He has achieved this in partnership with Paragon Biosciences which shares the same vision. Jeff Aronin is a board member of the World Business Chicago that creates a partnership between private companies and the city to ensure growth. He was appointed to this position by Rahm Emanuel, the mayor of Chicago. He also serves as a member of the board of directors of Discover Financial Services. He has built a foundation that does research and patience advocacy for overlooked diseases.

 

Jorge Moll and His Study on RSATL-SCSR Connectivity for JAMA Psychiatry

The world already knows that Jorge Moll is one of the most prolific and persistent research leaders today in the field of cognitive neuroscience. However, what makes him even more popular and well-cited in many research papers is the fact that in November 2015 he was able to present a convincing set of results for JAMA Psychiatry about the dynamics behind self-blame-selective hyperconnectivity. In his particular study, he found a link between anterior temporal and subgenual cortices and how it can present a prediction for depressive episodes.

 

In the study’s abstract, it was argued that many patients suffering from Major Depressive Disorder (MDD) had already previously shown signs of abnormality in their functional magnetic resonance imaging connectivity (fMRI) between the subgenual cingulate cortex and adjacent septal region (SCSR), and the right superior anterior temporal lobe (RSATL). All of these elements have a substantial contribution to how likely a specialist can detect a tendency of patients to aggravate their state of depression.

 

The remarkable thing about this particular study of Jorge Moll is in the fact that it can provide a robust neural signature that is the foundation of overgeneralized self-blaming emotions. With such results, it is now more likely for a physician to find a risk of recurrence for depression and for establishing a benchmark for prognostic biomarkers that can help in the treatment. We should also indicate here that the study also resulted in confirming the hypothesis that RSATL-SCSR connectivity can predict risk of subsequent recurrence of primary depressive disorder symptoms.

 

Jorge Moll’s Involvement

 

It’s not an exaggeration to state here that Jorge Moll, Director of D’Or Institute for Research and Education (IDOR), has played an invaluable role in the study above, along with other remarkable research studies. In 2005, his study on the neural basis of moral cognition had gained about 925 citations, while in 2006, his work on human frontal-mesolimbic networks gained about 821 quotations. All of this is a strong indication of Mr. Moll’s dedication in cognitive neuroscience and in the passionate search for remedies of social behavior ailments.